Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata

Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata

(2020) Taisuke Ito et al.   EXPERIMENTAL DERMATOLOGY

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

(2018) A. Jabbari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3

(2018) Katia Boniface et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin

(2017) Stanley Cheuk et al.   IMMUNITY

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

(2017) Fiona Elwood et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses

(2017) Andrea Majoros et al.   Frontiers in Immunology

Alopecia areata

(2017) C. Herbert Pratt et al.   Nature Reviews Disease Primers

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition

(2016) Jean-Baptiste Telliez et al.   ACS Chemical Biology

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

(2016) John O. Mascarenhas et al.   HAEMATOLOGICA

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

(2016) Robert Bissonnette et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata

(2016) Zhenpeng Dai et al.   JOURNAL OF IMMUNOLOGY

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

(2016) Geoffrey A Smith et al.   Nature Chemical Biology

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

(2016) John O. Mascarenhas et al.   HAEMATOLOGICA

The role of lymphocytes in the development and treatment of alopecia areata

(2015) Hongwei Guo et al.   Expert Review of Clinical Immunology

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function

(2015) F Perner et al.   LEUKEMIA

Resident memory T cells in human health and disease

(2015) R. A. Clark   Science Translational Medicine

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Selective inhibitors of the Janus kinase Jak3—Are they effective?

(2014) Gebhard Thoma et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis

(2014) S. Cheuk et al.   JOURNAL OF IMMUNOLOGY

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

(2011) Claude Haan et al.   CHEMISTRY & BIOLOGY

CXCR3 ligands: redundant, collaborative and antagonistic functions

(2011) Joanna R Groom et al.   IMMUNOLOGY AND CELL BIOLOGY

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

(2011) L. D. Lu et al.   JOURNAL OF IMMUNOLOGY

Type 1 interferon signature in the scalp lesions of alopecia areata

(2010) M. Ghoreishi et al.   BRITISH JOURNAL OF DERMATOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY